English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Clostridium difficile-associated diarrhea (CDAD) is common during hematopoietic stem-cell transplantation (HSCT) and is associated with increased morbidity and mortality. We evaluated fidaxomicin for prevention of CDAD in HSCT patients.

clinical infectious diseases/clinical infectious diseases (online. university of chicago. press)

A Randomized, Placebo-controlled Trial of Fidaxomicin for Prophylaxis of<i>Clostridium difficile–</i>associated Diarrhea in Adults Undergoing Hematopoietic Stem Cell Transplantation

A Randomized, Placebo-controlled Trial of Fidaxomicin for Prophylaxis ofClostridium difficile–associated Diarrhea in Adults Undergoing Hematopoietic Stem Cell Transplantation